Product category:
Contract research
News Release from: Acrongenomics
Edited by the Laboratorytalk Editorial
Team on 29 December 2005
$4million to fund ongoing operations
Acrongenomics will use the net proceeds for the ongoing development of the Nano-Jeta platform as well as general corporate purposes
Acrongenomics, a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, has announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday 16 December 2005 "The success of this financing illustrates a strong confirmation of our approach, giving us the opportunity to focus on delivering advanced nanotechnology research to the life sciences industry
"By putting together our scientific excellence and strong financial base, we have managed to complete this private placement financing earlier than expected," said Constantine Poulios, Acrongenomics's vice president.
Acrongenomics also announces that it is proceeding to obtain an independent evaluation of its technology from a certified reference laboratory.
• Acrongenomics: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
